PDF) Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation | Raghavan Vidya - Academia.edu
The Truth About Estrogen and Cancer
Systemic therapy for early-stage breast cancer: learning from the past to build the future | Nature Reviews Clinical Oncology
Frontiers | GRPR-targeting radiotheranostics for breast cancer management
Frontiers | Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
Dr Pusztai on the Launch of the DARE Study in ER+/HER2– High-Risk Breast Cancer
Dr Pusztai on the Launch of the DARE Study in ER+/HER2– High-Risk Breast Cancer
Frontiers | Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023 | Natera
PDF) Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors | Marieke van Leeuwen and Hester Oldenburg - Academia.edu
Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications | EJNMMI Research | Full Text
Breast cancer | Nature Reviews Disease Primers
JPM | Free Full-Text | Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories
Breast Cancer Clinical Trials in East Africa | Current Breast Cancer Reports
Studypages - DNA-Guided Second Line Adjuvant Therapy for High Residual Risk, Stage II-III, HR-positive, HER2-negative Breast Cancer (DARE)
Signatera Test for Residual Disease Will Be Used in Breast Cancer Trial
Breast Cancer Clinical Trials in East Africa | Current Breast Cancer Reports
Neoadjuvant Trastuzumab and Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer | Research To Practice
dare-20211231
Cells | Free Full-Text | Circulating Tumor DNA in the Management of Early-Stage Breast Cancer
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? | npj Breast Cancer
Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications | EJNMMI Research | Full Text
Circulating Tumor DNA in Breast Cancer: Current and Future Applications - ScienceDirect
DARÉ BIOSCIENCE, INC.
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges | British Journal of Cancer
Cells | Free Full-Text | Circulating Tumor DNA in the Management of Early-Stage Breast Cancer
Secondary HR+ Breast cancer - What've hormones got to do with it? - OWise UK
Systemic therapy for early-stage breast cancer: learning from the past to build the future | Nature Reviews Clinical Oncology
